Biofil Chemicals Publishes Newspaper Notice for SEBI Special Window Facility

2 min read     Updated on 03 Apr 2026, 01:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Biofil Chemicals and Pharmaceuticals Limited has published newspaper notices in Free Press Indore (English) and Choutha Sansar (Hindi) on April 3, 2026, to inform shareholders about SEBI's special window facility for transfer and dematerialization of physical securities. The facility, available from February 5, 2026 to February 4, 2027, covers securities sold or purchased before April 1, 2019, with mandatory demat credit and one-year lock-in period.

powered bylight_fuzz_icon
36590347

*this image is generated using AI for illustrative purposes only.

Biofil Chemicals and Pharmaceuticals Limited has published newspaper notices informing shareholders about the SEBI special window facility for transfer and dematerialization of physical securities. The company submitted the newspaper publication to BSE Limited and National Stock Exchange of India Limited on April 3, 2026.

Newspaper Publication Details

The company published notices in two newspapers on April 3, 2026, to create awareness among shareholders about the special window facility. The notices appeared in Free Press Indore (English) and Choutha Sansar (Hindi), ensuring coverage for both English and Hindi-speaking shareholders.

Publication Details: Information
Publication Date: April 3, 2026
English Newspaper: Free Press Indore
Hindi Newspaper: Choutha Sansar
Website Hosting: www.biofilgroup.net

SEBI Special Window Facility

The Securities and Exchange Board of India issued circular reference no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, regarding "Ease of Doing Investment – Special Window for Transfer and Dematerialisation of Physical Securities." This initiative facilitates investors holding physical securities that were sold or purchased prior to April 1, 2019.

Window Parameters: Details
Window Period: February 5, 2026 to February 4, 2027
Duration: One year
Applicable Securities: Sold/purchased before April 1, 2019
Lock-in Period: One year from transfer registration
Transfer Mode: Mandatory demat credit only

Facility Coverage and Requirements

The special window covers transfer requests that were previously submitted but faced rejection, return, or remained unattended due to documentation deficiencies or procedural requirements. All securities transferred through this facility will be mandatorily credited to the transferee in demat mode and will remain under lock-in for one year from the date of transfer registration.

During the lock-in period, these securities cannot be transferred, lien marked, or pledged. Shareholders must furnish required documents as mentioned in the SEBI circular to the company's Registrar and Share Transfer Agents.

Company Communication

The newspaper publication was submitted by Apoorv Jain, Company Secretary and Compliance Officer, who digitally signed the submission on April 3, 2026. The company has requested shareholders to take note of these regulatory initiatives and emphasized that the newspaper advertisements will also be hosted on the company's website.

Contact Information: Details
RTA: Ankit Consultancy Private Limited
RTA Email: investor@ankitononline.com
Company Email: bcplcompliance@gmail.com
Compliance Officer: Apoorv Jain (M. No. A71739)

Historical Stock Returns for Biofil Chemicals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.44%-5.51%-14.39%-33.89%-35.29%-60.30%

Will SEBI extend the February 2027 deadline for the special window facility if companies report low participation rates?

How might the one-year lock-in period affect Biofil Chemicals' stock liquidity and trading volumes once transfers are completed?

What percentage of Biofil's outstanding shares are estimated to be in physical form and eligible for this transfer window?

Biofil Chemicals and Pharmaceuticals Limited Publishes Unaudited Financial Results for Q3 FY25

1 min read     Updated on 14 Feb 2026, 06:43 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Biofil Chemicals and Pharmaceuticals Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025, in Free Press Mumbai & Indore and Choutha Sansar newspapers on February 14, 2026. The publication complies with SEBI Listing Obligations and Disclosure Requirements Regulations 2015, following board approval on February 13, 2026. The results include Quick Response Code and webpage access for complete financial information.

powered bylight_fuzz_icon
32620433

*this image is generated using AI for illustrative purposes only.

Biofil chemicals and Pharmaceuticals Limited has published its unaudited financial results for the quarter and nine months ended December 31, 2025, in compliance with SEBI regulations. The company made the announcement through newspaper publications on February 14, 2026.

Regulatory Compliance and Publication Details

The financial results were published in accordance with Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company ensured wide accessibility by publishing the results in both English and Hindi newspapers.

Publication Details: Information
Publication Date: February 14, 2026
English Newspaper: Free Press Mumbai & Indore
Hindi Newspaper: Choutha Sansar
Board Approval Date: February 13, 2026
Results Period: Quarter and nine months ended December 31, 2025

Company Information and Accessibility

Biofil Chemicals and Pharmaceuticals Limited operates with CIN L24233MP1985PLC002709 and maintains its registered office at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.). The company has made the complete financial results accessible through multiple channels to ensure transparency.

The newspaper publications include Quick Response Code and webpage information, allowing stakeholders to access comprehensive financial data. The complete results are also available on the company's official website at www.biofilgroup.net .

Corporate Governance and Documentation

Company Secretary and Compliance Officer Apoorv Jain (M. No. A71739) signed the regulatory submission, ensuring proper documentation and compliance procedures. The submission was digitally signed on February 14, 2026, at 12:48:18 +05'30', demonstrating the company's commitment to modern corporate governance practices.

The financial results cover both quarterly performance and nine-month cumulative data, providing stakeholders with comprehensive insights into the company's financial position for the specified period ending December 31, 2025.

Source:

Historical Stock Returns for Biofil Chemicals

1 Day5 Days1 Month6 Months1 Year5 Years
-0.44%-5.51%-14.39%-33.89%-35.29%-60.30%

More News on Biofil Chemicals

1 Year Returns:-35.29%